Dr. Bin Xu is a Principal Investigator at the BRITE Institute of North Carolina Central University and an affiliated faculty with Duke/UNC Alzheimer's Disease Research Center. He also serves as Co-Director of Neurobehavioral Core at NCCU. His lab concerns the areas of translational aging research, in particular, misfolded tau-based new biomarker discovery for early Alzheimer's diagnosis, differentiation of AD and related tauopathies, and drug discovery against protein misfolding diseases such as Alzheimer's and type 2 diabetes. Dr. Xu obtained his PhD in Biochemistry from Case Western Reserve University and completed his postdoctral fellowship in Structural and Molecular Immunology at Fred Hutchinson Cancer Research Center.

Dr Xu is an assistant professor working in Prof. Maria Eriksdotter’s group at the Div. of Clinical Geriatrics, NVS, Karolinska institute. Her research focuses on the association between chronic inflammatory diseases such as kidney disease and dementia, particularly acute and chronic kidney disease. Dr. Xu obtained her Ph.D. at Dep of Medical Epidemiology and Biostatistics (MEB), Karolinska Institutet. Before her Ph.D., she was a Nephrologist in Div of Nephrology, at Peking Union Medical College Hospital. Her research grants include the Swedish research council (Vetenskapsrådet), CIMED, Åke Wibergs Stiftelse, Stiftelsen För Gamla Tjänarinnor, StratNeuro, and KI foundation.

Xiao Xu is a co-founder of Cerevance, a company that is discovering new treatments for brain diseases. In her postdoctoral work with Nathaniel Heintz at The Rockefeller University, Xiao developed the NETSseq technology platform, which Cerevance is using to comprehensively profile specific brain cell types using post-mortem human brain tissue. These studies have enabled identification of novel targets for diseases including Parkinson's and Alzheimer's. Before Rockefeller, she worked on gene expression networks in aging during her PhD work at Stanford University.